Histone deacetylase: a potential target for the treatment of atrial fibrillation_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

QIN Xiaoli , ZHANG Tailong ,  WU Zhong

Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

WU Zhong, Email: wuzhong_71@163.com

Keywords：

Histone deacetylase; atrial fibrillation; atrial remodeling

DOI：

10.7507/1007-4848.201907003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Atrial fibrillation is a common arrhythmia associated with high mortality and morbidity, and the current treatment of atrial fibrillation is still limited. Histone deacetylase (HDAC) plays an important role in the pathophysiology of cardiovascular disease and promotes the occurrence of atrial fibrillation. Inhibition of HDAC may be a new therapeutic strategy through the regulation of atrial remodeling. Therefore, we reviewed the research progress of the HDAC and atrial fibrillation.

Citation： QIN Xiaoli, ZHANG Tailong, WU Zhong. Histone deacetylase: a potential target for the treatment of atrial fibrillation. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(2): 214-217. doi: 10.7507/1007-4848.201907003 Copy

1.	Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol, 2014, 63(22): 2335-2345.
2.	Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell, 2008, 31(4): 449-461.
3.	Eom GH, Kook H. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Pharmacol Ther, 2014, 143(2): 168-180.
4.	Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem, 2004, 93(1): 57-67.
5.	Barry SP, Townsend PA. What causes a broken heart--molecular insights into heart failure. Int Rev Cell Mol Biol, 2010, 284: 113-179.
6.	Morin S, Charron F, Robitaille L, et al. GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J, 2000, 19(9): 2046-2055.
7.	Dzeshka MS, Lip GY, Snezhitskiy V, et al. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol, 2015, 66(8): 943-959.
8.	Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer, 2004, 112(2): 171-178.
9.	Tao H, Shi K H, Yang JJ, et al. Epigenetic regulation of cardiac fibrosis. Cell signal, 2013, 25(9): 1932-1938.
10.	Xie M, Hill JA. HDAC-dependent ventricular remodeling. Trends Cardiovasc Med, 2013, 23(6): 229-235.
11.	Nural-Guvener HF, Zakharova L, Nimlos J, et al. HDAC classⅠinhibitor, mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair, 2014, 7: 10.
12.	Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res, 2004, 94(11): 1458-1465.
13.	Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta, 2007, 1773(10): 1572-1582.
14.	Cho JS, Moon YM, Park IH, et al. Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts. Clin Exp Allergy, 2012, 42(6): 872-882.
15.	Tao H, Yang JJ, Hu W, et al. HDAC6 promotes cardiac fibrosis progression through suppressing RASSF1A expression. Cardiology, 2016, 133(1): 18-26.
16.	Tsai YT, Lin FY, Lin CS, et al. B-type natriuretic peptide enhances fibrotic effects via matrix metalloproteinase-2 expression in the mouse atrium in vivo and in human atrial myofibroblasts in vitro. Transl Res, 2019, 208: 30-46.
17.	Zhang D, Wu CT, Qi X, et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation, 2014, 129(3): 346-358.
18.	Zhang L, Chen B, Zhao Y, et al. Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts. J Biol Chem, 2012, 287(47): 39338-39348.
19.	Zhang L, Hu Y, Yan S, et al. ABA-mediated inhibition of seed germination is associated with ribosomal DNA chromatin condensation, decreased transcription, and ribosomal RNA gene hypoacetylation. Plant Mol Biol, 2012, 79(3): 285-293.
20.	Lee TM, Lin MS, Chang NC. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol, 2007, 293(2): H968-H977.
21.	Liu F, Levin MD, Petrenko NB, et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol, 2008, 45(6): 715-723.
22.	Orenes-Piñero E, Montoro-García S, Patel JV, et al. Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol, 2013, 167(5): 1651-1659.
23.	Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res, 2009, 104(2): 170-178.
24.	Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res, 2010, 106(1): 166-175.
25.	Renaud L, Harris LG, Mani SK, et al. HDACs Regulate miR-133a expression in pressure overload-induced cardiac fibrosis. Circ Heart Fail, 2015, 8(6): 1094-1104.
26.	Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev, 2007, 21(14): 1790-1802.
27.	Lugenbiel P, Govorov K, Rahm AK, et al. Inhibition of histone deacetylases induces K+ channel remodeling and action potential prolongation in HL-1 atrial cardiomyocytes. Cell Physiol Biochem, 2018, 49(1): 65-77.
28.	Lkhagva B, Chang SL, Chen YC, et al. Histone deacetylase inhibition reduces pulmonary vein arrhythmogenesis through calcium regulation. Int J Cardiol, 2014, 177(3): 982-989.
29.	Chang CJ, Li SJ, Chen YC, et al. Histone deacetylase inhibition attenuates atrial arrhythmogenesis in sterile pericarditis. Transl Res, 2018, 200: 54-64.
30.	Scholz B, Schulte JS, Hamer S, et al. HDAC (histone deacetylase) inhibitor valproic acid attenuates atrial remodeling and delays the onset of atrial fibrillation in mice. Circ Arrhythm Electrophysiol, 2019, 12(3): e007071.
31.	Ashjian E, Redic K. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. J Oncol Pharm Pract, 2016, 22(2): 289-302.
32.	Zhang D, Hu X, Li J, et al. Converse role of classⅠand classⅡa HDACs in the progression of atrial fibrillation. J Mol Cell Cardiol, 2018, 125: 39-49.
33.	van Marion DM, Lanters EA, Wiersma M, et al. Diagnosis and therapy of atrial fibrillation: the past, the present and the future. J Atr Fibrillation, 2015, 8(2): 1216.

1. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol, 2014, 63(22): 2335-2345.
2. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell, 2008, 31(4): 449-461.
3. Eom GH, Kook H. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases. Pharmacol Ther, 2014, 143(2): 168-180.
4. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem, 2004, 93(1): 57-67.
5. Barry SP, Townsend PA. What causes a broken heart--molecular insights into heart failure. Int Rev Cell Mol Biol, 2010, 284: 113-179.
6. Morin S, Charron F, Robitaille L, et al. GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J, 2000, 19(9): 2046-2055.
7. Dzeshka MS, Lip GY, Snezhitskiy V, et al. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol, 2015, 66(8): 943-959.
8. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer, 2004, 112(2): 171-178.
9. Tao H, Shi K H, Yang JJ, et al. Epigenetic regulation of cardiac fibrosis. Cell signal, 2013, 25(9): 1932-1938.
10. Xie M, Hill JA. HDAC-dependent ventricular remodeling. Trends Cardiovasc Med, 2013, 23(6): 229-235.
11. Nural-Guvener HF, Zakharova L, Nimlos J, et al. HDAC classⅠinhibitor, mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair, 2014, 7: 10.
12. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res, 2004, 94(11): 1458-1465.
13. Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta, 2007, 1773(10): 1572-1582.
14. Cho JS, Moon YM, Park IH, et al. Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts. Clin Exp Allergy, 2012, 42(6): 872-882.
15. Tao H, Yang JJ, Hu W, et al. HDAC6 promotes cardiac fibrosis progression through suppressing RASSF1A expression. Cardiology, 2016, 133(1): 18-26.
16. Tsai YT, Lin FY, Lin CS, et al. B-type natriuretic peptide enhances fibrotic effects via matrix metalloproteinase-2 expression in the mouse atrium in vivo and in human atrial myofibroblasts in vitro. Transl Res, 2019, 208: 30-46.
17. Zhang D, Wu CT, Qi X, et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation, 2014, 129(3): 346-358.
18. Zhang L, Chen B, Zhao Y, et al. Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts. J Biol Chem, 2012, 287(47): 39338-39348.
19. Zhang L, Hu Y, Yan S, et al. ABA-mediated inhibition of seed germination is associated with ribosomal DNA chromatin condensation, decreased transcription, and ribosomal RNA gene hypoacetylation. Plant Mol Biol, 2012, 79(3): 285-293.
20. Lee TM, Lin MS, Chang NC. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol, 2007, 293(2): H968-H977.
21. Liu F, Levin MD, Petrenko NB, et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol, 2008, 45(6): 715-723.
22. Orenes-Piñero E, Montoro-García S, Patel JV, et al. Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol, 2013, 167(5): 1651-1659.
23. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res, 2009, 104(2): 170-178.
24. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res, 2010, 106(1): 166-175.
25. Renaud L, Harris LG, Mani SK, et al. HDACs Regulate miR-133a expression in pressure overload-induced cardiac fibrosis. Circ Heart Fail, 2015, 8(6): 1094-1104.
26. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev, 2007, 21(14): 1790-1802.
27. Lugenbiel P, Govorov K, Rahm AK, et al. Inhibition of histone deacetylases induces K+ channel remodeling and action potential prolongation in HL-1 atrial cardiomyocytes. Cell Physiol Biochem, 2018, 49(1): 65-77.
28. Lkhagva B, Chang SL, Chen YC, et al. Histone deacetylase inhibition reduces pulmonary vein arrhythmogenesis through calcium regulation. Int J Cardiol, 2014, 177(3): 982-989.
29. Chang CJ, Li SJ, Chen YC, et al. Histone deacetylase inhibition attenuates atrial arrhythmogenesis in sterile pericarditis. Transl Res, 2018, 200: 54-64.
30. Scholz B, Schulte JS, Hamer S, et al. HDAC (histone deacetylase) inhibitor valproic acid attenuates atrial remodeling and delays the onset of atrial fibrillation in mice. Circ Arrhythm Electrophysiol, 2019, 12(3): e007071.
31. Ashjian E, Redic K. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. J Oncol Pharm Pract, 2016, 22(2): 289-302.
32. Zhang D, Hu X, Li J, et al. Converse role of classⅠand classⅡa HDACs in the progression of atrial fibrillation. J Mol Cell Cardiol, 2018, 125: 39-49.
33. van Marion DM, Lanters EA, Wiersma M, et al. Diagnosis and therapy of atrial fibrillation: the past, the present and the future. J Atr Fibrillation, 2015, 8(2): 1216.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Histone deacetylase: a potential target for the treatment of atrial fibrillation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content